Invasive group B streptococcal disease in non-pregnant adults: A review with emphasis on skin and soft-tissue infections

Infection

Volumn 36, Issue 2, 2008, Pages 100-111

  Sendi, P ^a,b   Johansson, L ^a   Norrby Teglund, A ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIUM ANTIBODY; CEFOTAXIME; CEFTRIAXONE; CLINDAMYCIN; ERYTHROMYCIN; GENTAMICIN; IMMUNOGLOBULIN; LEVOFLOXACIN; MACROLIDE; MEROPENEM; PENICILLIN G; PENICILLIN V; VANCOMYCIN; VIRULENCE FACTOR;

AGE DISTRIBUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; CELL INVASION; CELLULITIS; CLINICAL FEATURE; DECUBITUS; DIABETES MELLITUS; DISEASE PREDISPOSITION; DRUG POTENTIATION; ERYSIPELAS; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION RISK; LIVER CIRRHOSIS; NECROTIZING FASCIITIS; NEOPLASM; NEUROGENIC BLADDER; NURSING HOME PATIENT; PATHOGENESIS; REVIEW; SKIN INFECTION; SKIN ULCER; SOFT TISSUE INFECTION; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS INFECTION; STROKE; TOXIC SHOCK SYNDROME; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; FASCIITIS, NECROTIZING; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; MALE; RISK FACTORS; SHOCK, SEPTIC; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE;

EID: 42249084239     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-007-7251-0     Document Type: Review

References (139)

1. Schrag SJ, Zywicki S, Farley MM, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 2000; 342: 15-20.
2. Munoz P, Llancaqueo A, Rodriguez-Creixems M, Pelaez T, Martin L, Bouza E: Group B streptococcus bacteremia in nonpregnant adults. Arch Intern Med 1997; 157: 213-216.
3. Active Bacterial Core Surveillance (ABCs) Report, Emerging Infections Program Network, group B streptococcus, 2005: Centers for Disease Control and Prevention, 2007.
4. Schwartz B, Schuchat A, Oxtoby MJ, Cochi SL, Hightower A, Broome CV: Invasive group B streptococcal disease in adults. A population-based study in metropolitan Atlanta. Jama 1991; 266: 1112-1114.
5. Zangwill KM, Schuchat A, Wenger JD: Group B streptococcal disease in the United States, 1990: report from a multistate active surveillance system. MMWR CDC Surveill Summ 1992; 41: 25-32.
6. Farley MM, Harvey RC, Stull T, et al. A population-based assessment of invasive disease due to group B Streptococcus in nonpregnant adults. N Engl J Med 1993; 328: 1807-1811.
7. Blancas D, Santin M, Olmo M, Alcaide F, Carratala J, Gudiol F: Group B streptococcal disease in nonpregnant adults: incidence, clinical characteristics, and outcome. Eur J Clin Microbiol Infect Dis 2004; 23: 168-173.
8. Huang PY, Lee MH, Yang CC, Leu HS: Group B streptococcal bacteremia in non-pregnant adults. J Microbiol Immunol Infect 2006; 39: 237-241.
9. Wang TK, Fung AM, Woo PC, Yuen KY, Wong SS: Streptococcus agalactiae (Lancefield group B) bacteraemia in nonpregnant adults. Eur J Clin Microbiol Infect Dis 2002; 21: 140-142.
10. Harrison LH, Ali A, Dwyer DM, et al. Relapsing invasive group B streptococcal infection in adults. Ann Intern Med 1995; 123: 421-427.
11. Jackson LA, Hilsdon R, Farley MM, et al. Risk factors for group B streptococcal disease in adults. Ann Intern Med 1995; 123: 415-420.
12. Cox NH: Oedema as a risk factor for multiple episodes of cellulitis/ erysipelas of the lower leg: a series with community follow-up. Br J Dermatol 2006; 155: 947-950.
13. Lee NY, Yan JJ, Wu JJ, Lee HC, Liu KH, Ko WC: Group B streptococcal soft tissue infections in non-pregnant adults. Clin Microbiol Infect 2005; 11: 577-579.
14. Opal SM, Cross A, Palmer M, Almazan R: Group B streptococcal sepsis in adults and infants. Contrasts and comparisons. Arch Intern Med 1988; 148: 641-645.
15. Ho CM, Chi CY, Ho MW, et al. Clinical characteristics of group B streptococcus bacteremia in non-pregnant adults. J Microbiol Immunol Infect 2006; 39: 396-401.
16. Kim BN, Bae IG, Kim MN, Woo JH, Ryu J, Kim YS: Group B streptococcal bacteremia in nonpregnant adults with hepatic disease in Korea. Eur J Clin Microbiol Infect Dis 2001; 20: 639-642.
17. Colford JM Jr., Mohle-Boetani J, Vosti KL: Group B streptococcal bacteremia in adults. Five years' experience and a review of the literature. Medicine (Baltimore) 1995; 74: 176-190.
18. Baddour LM, Cox JW Jr: Group B streptococcal infection of a pacemaker wire following sigmoidoscopy. Clin Infect Dis 1992; 15: 1069.
19. Triesenberg SN, Clark NM, Kauffman CA: Group B streptococcal prosthetic joint infection following sigmoidoscopy. Clin Infect Dis 1992; 15: 374-375.
20. Trivalle C, Martin E, Martel P, Jacque B, Menard JF, Lemeland JF: Group B streptococcal bacteraemia in the elderly. J Med Microbiol 1998; 47: 649-652.
21. Manning SD, Tallman P, Baker CJ, Gillespie B, Marrs CF, Foxman B: Determinants of co-colonization with group B streptococcus among heterosexual college couples. Epidemiology 2002; 13: 533-539.
22. Easmon CS, Tanna A, Munday P, Dawson S: Group B streptococci- gastrointestinal organisms? J Clin Pathol 1981; 34: 921-3.
23. Meyn LA, Moore DM, Hillier SL, Krohn MA: Association of sexual activity with colonization and vaginal acquisition of group B Streptococcus in nonpregnant women. Am J Epidemiol 2002; 155: 949-957.
24. Manning SD, Neighbors K, Tallman PA, et al. Prevalence of group B streptococcus colonization and potential for transmission by casual contact in healthy young men and women. Clin Infect Dis 2004; 39: 380-388.
25. Brimil N, Barthell E, Heindrichs U, Kuhn M, Lutticken R, Spellerberg B: Epidemiology of Streptococcus agalactiae colonization in Germany. Int J Med Microbiol 2006; 296: 39-44.
26. Edwards MS, Rench MA, Palazzi DL, Baker CJ: Group B streptococcal colonization and serotype-specific immunity in healthy elderly persons. Clin Infect Dis 2005; 40: 352-357.
27. Manning S, Tallman P, Foxman B: Prevalence and co-colonization with group b streptococcus (Gbs) Among heterosexual college couples. Ann Epidemiol 2000; 10: 472.
28. Lindahl G, Stalhammar-Carlemalm M, Areschoug T: Surface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens. Clin Microbiol Rev 2005; 18: 102-127.
29. Tyrrell GJ, Senzilet LD, Spika JS, et al. Invasive disease due to group B streptococcal infection in adults: results from a Canadian, population-based, active laboratory surveillance study - 1996. Sentinel Health Unit Surveillance System Site Coordinators. J Infect Dis 2000; 182: 168-173.
30. Harrison LH, Elliott JA, Dwyer DM, et al. Serotype distribution of invasive group B streptococcal isolates in Maryland: implications for vaccine formulation. Maryland Emerging Infections Program. J Infect Dis 1998; 177: 998-1002.
31. Blumberg HM, Stephens DS, Modansky M, et al. Invasive group B streptococcal disease: the emergence of serotype V. J Infect Dis 1996; 173: 365-373.
32. Hickman ME, Rench MA, Ferrieri P, Baker CJ: Changing epidemiology of group B streptococcal colonization. Pediatrics 1999; 104: 203-209.
33. Farley MM: Group B streptococcal disease in nonpregnant adults. Clin Infect Dis 2001; 33: 556-561.
34. Lachenauer CS, Kasper DL, Shimada J, et al. Serotypes VI and VIII predominate among group B streptococci isolated from pregnant Japanese women. J Infect Dis 1999; 179: 1030-1033.
35. Ekelund K, Slotved HC, Nielsen HU, Kaltoft MS, Konradsen HB: Emergence of invasive serotype VIII group B streptococcal infections in Denmark. J Clin Microbiol 2003; 41: 4442-4444.
36. Murdoch DR, Reller LB: Antimicrobial susceptibilities of group B streptococci isolated from patients with invasive disease: 10-year perspective. Antimicrob Agents Chemother 2001; 45: 3623-3634.
37. Fernandez M, Hickman ME, Baker CJ: Antimicrobial susceptibilities of group B streptococci isolated between 1992 and 1996 from patients with bacteremia or meningitis. Antimicrob Agents Chemother 1998; 42: 1517-1519.
38. DiPersio LP, DiPersio JR: High rates of erythromycin and clindamycin resistance among OBGYN isolates of group B Streptococcus. Diagn Microbiol Infect Dis 2006; 54: 79-82.
39. von Both U, Buerckstuemmer A, Fluegge K, Berner R: Heterogeneity of genotype-phenotype correlation among macrolide-resistant Streptococcus agalactiae isolates. Antimicrob Agents Chemother 2005; 49: 3080-3082.
40. von Both U, Ruess M, Mueller U, Fluegge K, Sander A, Berner R: A serotype V clone is predominant among erythromycin-resistant Streptococcus agalactiae isolates in a southwestern region of Germany. J Clin Microbiol 2003; 41: 2166-2169.
41. Lin FY, Azimi PH, Weisman LE, et al. Antibiotic susceptibility profiles for group B streptococci isolated from neonates, 1995-1998. Clin Infect Dis 2000; 31: 76-79.
42. Manning SD, Foxman B, Pierson CL, Tallman P, Baker CJ, Pearlman MD: Correlates of antibiotic-resistant group B streptococcus isolated from pregnant women. Obstet Gynecol 2003; 101: 74-79.
43. Uh Y, Kim HY, Jang IH, Hwang GY, Yoon KJ: Correlation of serotypes and genotypes of macrolide-resistant Streptococcus agalactiae. Yonsei Med J 2005; 46: 480-483.
44. Murray P, Rosenthal K, Pfaller M. Medical Microbiology. 5th ed. Philadelphia, 2005; 247-250.
45. Picard FJ, Bergeron MG: Laboratory detection of group B Streptococcus for prevention of perinatal disease. Eur J Clin Microbiol Infect Dis 2004; 23: 665-671.
46. Nizet V, Gibson RL, Chi EY, Framson PE, Hulse M, Rubens CE: Group B streptococcal beta-hemolysin expression is associated with injury of lung epithelial cells. Infect Immun 1996; 64: 3818-3826.
47. Edwards MS, Baker CJ: Group B streptococcal infections in elderly adults. Clin Infect Dis 2005; 41: 839-847.
48. Del Giudice P, van der Mee-Marquet N, David-Rubin F, et al. Severe relapsing erysipelas associated with chronic Streptococcus agalactiae vaginal colonization. Clin Infect Dis 2006; 43: e67-e70.
49. Sendi P, Graber P, Johansson L, Norrby-Teglund A, Zimmerli W: Streptococcus agalactiae in relapsing cellulitis. Clin Infect Dis 2007; 44: 1141-1142.
50. Bero SM, Brady MS: Streptococcal septic shock after inguinal lymphadenectomy. Surg Infect (Larchmt) 2006; 7: 547-550.
51. Binnick AN, Klein RB, Baughman RD: Recurrent erysipelas caused by group B streptococcus organisms. Arch Dermatol 1980; 116: 798-799.
52. Clement S, Vaudaux P, Francois P, et al. Evidence of an intracellular reservoir in the nasal mucosa of patients with recurrent Staphylococcus aureus rhinosinusitis. J Infect Dis 2005; 192: 1023-1028.
53. Thulin P, Johansson L, Low DE, et al. Viable group A streptococci in macrophages during acute soft tissue infection. PLoS Med 2006; 3: e53.
54. Baker CJ, Edwards MS, Kasper DL: Role of antibody to native type III polysaccharide of group B Streptococcus in infant infection. Pediatrics 1981; 68: 544-549.
55. Kasper DL, Paoletti LC, Wessels MR, et al. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest 1996; 98: 2308-2314.
56. Baker CJ, Paoletti LC, Wessels MR, et al. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J Infect Dis 1999; 179: 142-150.
57. Baker CJ, Paoletti LC, Rench MA, et al. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women. J Infect Dis 2000; 182: 1129-1138.
58. Amaya RA, Baker CJ, Keitel WA, Edwards MS: Healthy elderly people lack neutrophil-mediated functional activity to type V group B Streptococcus. J Am Geriatr Soc 2004; 52: 46-50.
59. Palazzi DL, Rench MA, Edwards MS, Baker CJ: Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old. J Infect Dis 2004; 190: 558-564.
60. Baker CJ, Webb BJ, Kasper DL, Edwards MS: The role of complement and antibody in opsonophagocytosis of type II group B streptococci. J Infect Dis 1986; 154: 47-54.
61. Mazade MA, Edwards MS: Impairment of type III group B Streptococcus-stimulated superoxide production and opsonophagocytosis by neutrophils in diabetes. Mol Genet Metab 2001; 73: 259-267.
62. Cotter PA, Miller JF: In vivo and ex vivo regulation of bacterial virulence gene expression. Curr Opin Microbiol 1998; 1: 17-26.
63. Tamura GS, Kuypers JM, Smith S, Raff H, Rubens CE: Adherence of group B streptococci to cultured epithelial cells: roles of environmental factors and bacterial surface components. Infect Immun 1994; 62: 2450-2458.
64. Spellerberg B, Rozdzinski E, Martin S, Weber-Heynemann J, Lutticken R: rgf encodes a novel two-component signal transduction system of Streptococcus agalactiae. Infect Immun 2002; 70: 2434-2440.
65. Poyart C, Lamy MC, Boumaila C, Fiedler F, Trieu-Cuot P: Regulation of D-alanyl-lipoteichoic acid biosynthesis in Streptococcus agalactiae involves a novel two-component regulatory system. J Bacteriol 2001; 183: 6324-6334.
66. Jiang SM, Cieslewicz MJ, Kasper DL, Wessels MR: Regulation of virulence by a two-component system in group B streptococcus. J Bacteriol 2005; 187: 1105-1113.
67. Nizet V, Kim KS, Stins M, et al. Invasion of brain microvascular endothelial cells by group B streptococci. Infect Immun 1997; 65: 5074-5081.
68. Winram SB, Jonas M, Chi E, Rubens CE: Characterization of group B streptococcal invasion of human chorion and amnion epithelial cells In vitro. Infect Immun 1998; 66: 4932-4941.
69. Rubens CE, Smith S, Hulse M, Chi EY, van Belle G: Respiratory epithelial cell invasion by group B streptococci. Infect Immun 1992; 60: 5157-5163.
70. Lindahl G, Akerstrom B, Vaerman JP, Stenberg L: Characterization of an IgA receptor from group B streptococci: specificity for serum IgA. Eur J Immunol 1990; 20: 2241-2247.
71. Pleass RJ, Areschoug T, Lindahl G, Woof JM: Streptococcal IgA-binding proteins bind in the Calpha 2-Calpha 3 interdomain region and inhibit binding of IgA to human CD89. J Biol Chem 2001; 276: 8197-8204.
72. Marques MB, Kasper DL, Pangburn MK, Wessels MR: Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Infect Immun 1992; 60: 3986-3993.
73. Cheng Q, Stafslien D, Purushothaman SS, Cleary P: The group B streptococcal C5a peptidase is both a specific protease and an invasin. Infect Immun 2002; 70: 2408-2413.
74. Lin B, Averett WF, Novak J, et al. Characterization of PepB, a group B streptococcal oligopeptidase. Infect Immun 1996; 64: 3401-3406.
75. Poyart C, Pellegrini E, Gaillot O, Boumaila C, Baptista M, Trieu-Cuot P: Contribution of Mn-cofactored superoxide dismutase (SodA) to the virulence of Streptococcus agalactiae. Infect Immun 2001; 69: 5098-5106.
76. Madoff LC, Michel JL, Gong EW, Kling DE, Kasper DL: Group B streptococci escape host immunity by deletion of tandem repeat elements of the alpha C protein. Proc Natl Acad Sci U S A 1996; 93: 4131-4136.
77. Luan SL, Granlund M, Sellin M, Lagergard T, Spratt BG, Norgren M: Multilocus sequence typing of Swedish invasive group B streptococcus isolates indicates a neonatally associated genetic lineage and capsule switching. J Clin Microbiol 2005; 43: 3727-3733.
78. Cornacchione P, Scaringi L, Fettucciari K, et al. Group B streptococci persist inside macrophages. Immunology 1998; 93: 86-95.
79. Fettucciari K, Rosati E, Scaringi L, et al. Group B Streptococcus induces apoptosis in macrophages. J Immunol 2000; 165: 3923-3933.
80. Liu GY, Doran KS, Lawrence T, et al. Sword and shield: linked group B streptococcal beta-hemolysin/cytolysin and carotenoid pigment function to subvert host phagocyte defense. Proc Natl Acad Sci U S A 2004; 101: 14491-14496.
81. Wessels MR, Rubens CE, Benedi VJ, Kasper DL: Definition of a bacterial virulence factor: sialylation of the group B streptococcal capsule. Proc Natl Acad Sci U S A 1989; 86: 8983-89837.
82. Nizet V: Streptococcal beta-hemolysins: genetics and role in disease pathogenesis. Trends Microbiol 2002; 10: 575-580.
83. Doran KS, Chang JC, Benoit VM, Eckmann L, Nizet V: Group B streptococcal beta-hemolysin/cytolysin promotes invasion of human lung epithelial cells and the release of interleukin-8. J Infect Dis 2002; 185: 196-203.
84. Puliti M, Nizet V, von Hunolstein C, et al. Severity of group B streptococcal arthritis is correlated with beta-hemolysin expression. J Infect Dis 2000; 182: 824-832.
85. Lang S, Palmer M: Characterization of Streptococcus agalactiae CAMP factor as a pore-forming toxin. J Biol Chem 2003; 278: 38167-38173.
86. Begly JS, Barnes RC: Group B streptococcus toxic shock-like syndrome in a healthy woman: a case report. J Reprod Med 2007; 52: 323-325.
87. Schlievert PM, Gocke JE, Deringer JR: Group B streptococcal toxic shock-like syndrome: report of a case and purification of an associated pyrogenic toxin. Clin Infect Dis 1993; 17: 26-31.
88. Bessen DE, Hollingshead SK: Allelic polymorphism of emm loci provides evidence for horizontal gene spread in group A streptococci. Proc Natl Acad Sci U S A 1994; 91: 3280-3284.
89. Broker G, Spellerberg B: Surface proteins of Streptococcus agalactiae and horizontal gene transfer. Int J Med Microbiol 2004; 294: 169-175.
90. Gardam MA, Low DE, Saginur R, Miller MA: Group B streptococcal necrotizing fasciitis and streptococcal toxic shock-like syndrome in adults. Arch Intern Med 1998; 158: 1704-1708.
91. Wong CH, Kurup A, Tan KC: Group B Streptococcus necrotizing fasciitis: an emerging disease? Eur J Clin Microbiol Infect Dis 2004; 23: 573-575.
92. Chang B, Ikebe T, Wada A, et al. Surveillance of group B streptococcal toxic shock-like syndrome in nonpregnant adults and characterization of the strains in Japan. Jpn J Infect Dis 2006; 59: 182-185.
93. Puopolo KM, Klinzing DC, Lin MP, Yesucevitz DL, Cieslewicz MJ: A composite transposon associated with erythromycin and clindamycin resistance in group B Streptococcus. J Med Microbiol 2007; 56: 947-955.
94. Verghese A, Mireault K, Arbeit RD: Group B streptococcal bacteremia in men. Rev Infect Dis 1986; 8: 912-917.
95. Raja NS: Microbiology of diabetic foot infections in a teaching hospital in Malaysia: a retrospective study of 194 cases. J Microbiol Immunol Infect 2007; 40: 39-44.
96. Eriksson B, Jorup-Ronstrom C, Karkkonen K, Sjoblom AC, Holm SE: Erysipelas: clinical and bacteriologic spectrum and serological aspects. Clin Infect Dis 1996; 23: 1091-1098.
97. Perl B, Gottehrer NP, Raveh D, Schlesinger Y, Rudensky B, Yinnon AM: Cost-effectiveness of blood cultures for adult patients with cellulitis. Clin Infect Dis 1999; 29: 1483-1488.
98. Wong CH, Chang HC, Pasupathy S, Khin LW, Tan JL, Low CO. Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. J Bone Joint Surg Am 2003; 85-A: 1454-1460.
99. Crum NF, Wallace MR: Group B streptococcal necrotizing fasciitis and toxic shock-like syndrome: a case report and review of the literature. Scand J Infect Dis 2003; 35: 878-881.
100. Holmstrom B, Grimsley EW: Necrotizing fasciitis and toxic shock-like syndrome caused by group B streptococcus. South Med J 2000; 93: 1096-1098.
101. Akita S, Tanaka K, Hirano A: Lower extremity reconstruction after necrotising fasciitis and necrotic skin lesions using a porcine-derived skin substitute. J Plast Reconstr Aesthet Surg 2006; 59: 759-763.
102. Wong CH, Song C, Ong YS, Tan BK, Tan KC, Foo CL: Abdominal wall necrotizing fasciitis: it is still "Meleney's Minefield". Plast Reconstr Surg 2006; 117: 147e-150e.
103. Tang WM, Ho PL, Yau WP, Wong JW, Yip DK: Report of 2 fatal cases of adult necrotizing fasciitis and toxic shock syndrome caused by Streptococcus agalactiae. Clin Infect Dis 2000; 31: E15-E17.
104. Riefler J 3rd, Molavi A, Schwartz D, DiNubile M: Necrotizing fasciitis in adults due to group B streptococcus. Report of a case and review of the literature. Arch Intern Med 1988; 148: 727-729.
105. Kotb M, Norrby-Teglund A, McGeer A, et al. An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat Med 2002; 8: 1398-1404.
106. Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. The Working Group on Severe Streptococcal Infections. Jama 1993; 269: 390-391.
107. CDC. Streptococcal Toxic-Shock Syndrome (STSS); 1996 Case Definition. http://www.cdc.gov/epo/dphsi/casedef/streptococcalcurrent.htm.
108. Ekelund K, Skinhoj P, Madsen J, Konradsen HB: Invasive group A, B, C and G streptococcal infections in Denmark 1999-2002: epidemiological and clinical aspects. Clin Microbiol Infect 2005; 11: 569-576.
109. Sharma M, Khatib R, Fakih M: Clinical characteristics of necrotizing fasciitis caused by group G Streptococcus: case report and review of the literature. Scand J Infect Dis 2002; 34: 468-471.
110. Tee WS, Lieu PK, Ngan CC: Epidemiology of beta-haemolytic group G streptococcal bacteraemia in Singapore (1996 to 1998). Ann Acad Med Singapore 2002; 31: 86-91.
111. Hashikawa S, Iinuma Y, Furushita M, et al. Characterization of group C and G streptococcal strains that cause streptococcal toxic shock syndrome. J Clin Microbiol 2004; 42: 186-192.
112. Reich HL, Crawford GH, Pelle MT, James WD: Group B streptococcal toxic shock-like syndrome. Arch Dermatol 2004; 140: 163-166.
113. Gemmell CG: Susceptibility of a variety of clinical isolates to linezolid: a European inter-country comparison. J Antimicrob Chemother 2001; 48: 47-52.
114. Betriu C, Gomez M, Sanchez A, Cruceyra A, Romero J, Picazo JJ: Antibiotic resistance and penicillin tolerance in clinical isolates of group B streptococci. Antimicrob Agents Chemother 1994; 38: 2183-2186.
115. Schoening TE, Wagner J, Arvand M: Prevalence of erythromycin and clindamycin resistance among Streptococcus agalactiae isolates in Germany. Clin Microbiol Infect 2005; 11: 579-582.
116. Baker CN, Thornsberry C, Facklam RR: Synergism, killing kinetics, and antimicrobial susceptibility of group A and B streptococci. Antimicrob Agents Chemother 1981; 19: 716-725.
117. Paul M, Silbiger I, Grozinsky S, Soares-Weiser K, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2006: CD003344.
118. Buu-Hoi A, Le Bouguenec C, Horaud T: High-level chromosomal gentamicin resistance in Streptococcus agalactiae (group B). Antimicrob Agents Chemother 1990; 34: 985-988.
119. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41: 1373-1406.
120. Jorup-Ronstrom C, Britton S, Gavlevik A, Gunnarsson K, Redman AC: The course, costs and complications of oral versus intravenous penicillin therapy of erysipelas. Infection 1984; 12: 390-394.
121. Sjoblom AC, Bruchfeld J, Eriksson B, et al. Skin concentrations of phenoxymethylpenicillin in patients with erysipelas. Infection 1992; 20: 30-33.
122. Jacobs MR, Jones RN, Giordano PA: Oral beta-lactams applied to uncomplicated infections of skin and skin structures. Diagn Microbiol Infect Dis 2007; 57: S55-65.
123. Mascini EM, Jansze M, Schouls LM, Verhoef J, Van Dijk H: Penicillin and clindamycin differentially inhibit the production of pyrogenic exotoxins A and B by group A streptococci. Int J Antimicrob Agents 2001; 18: 395-398.
124. Stevens DL, Gibbons AE, Bergstrom R, Winn V: The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 1988; 158: 23-28.
125. Mulla ZD, Leaverton PE, Wiersma ST: Invasive group A streptococcal infections in Florida. South Med J 2003; 96: 968-973.
126. Stevens DL, Madaras-Kelly KJ, Richards DM: In vitro antimicrobial effects of various combinations of penicillin and clindamycin against four strains of Streptococcus pyogenes. Antimicrob Agents Chemother 1998; 42: 1266-1268.
127. Norrby-Teglund A, Muller MP, McGeer A, et al. Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach. Scand J Infect Dis 2005; 37: 166-172.
128. Darenberg J, Ihendyane N, Sjolin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003; 37: 333-340.
129. Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome - a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis 1999; 28: 800-807.
130. Moylett EH, Fernandez M, Rench MA, Hickman ME, Baker CJ: A 5-year review of recurrent group B streptococcal disease: lessons from twin infants. Clin Infect Dis 2000; 30: 282-287.
131. Gallagher PG, Watanakunakorn C: Group B streptococcal bacteremia in a community teaching hospital. Am J Med 1985; 78: 795-800.
132. Larppanichpoonphol P, Watanakunakorn C: Group B streptococcal bacteremia in nonpregnant adults at a community teaching hospital. South Med J 2001; 94: 1206-1211.
133. Schugk J, Harjola VP, Sivonen A, Vuopio-Varkila J, Valtonen M: A clinical study of beta-haemolytic groups A, B, C and G streptococcal bacteremia in adults over an 8-year period. Scand J Infect Dis 1997; 29: 233-238.
134. Henning KJ, Hall EL, Dwyer DM, et al. Invasive group B streptococcal disease in Maryland nursing home residents. J Infect Dis 2001; 183: 1138-1142.
135. Falagas ME, Rosmarakis ES, Avramopoulos I, Vakalis N: Streptococcus agalactiae infections in non-pregnant adults: Single center experience of a growing clinical problem. Med Sci Monit 2006; 12: CR447-CR451.
136. Skogberg K, Simonen H, Renkonen OV, Valtonen VV: Beta-haemolytic group A, B, C and G streptococcal septicaemia: a clinical study. Scand J Infect Dis 1988; 20: 119-125.
137. Lerner PI, Gopalakrishna KV, Wolinsky E, McHenry MC, Tan JS, Rosenthal M: Group B streptococcus (S. agalactiae) bacteremia in adults: analysis of 32 cases and review of the literature. Medicine (Baltimore) 1977; 56: 457-473.
138. Bayer AS, Chow AW, Anthony BF, Guze LB: Serious infections in adults due to group B streptococci. Clinical and serotypic characterization. Am J Med 1976; 61: 498-503.
139. Bolanos M, Canas A, Santana OE, Perez-Arellano JL, de Miguel I, Martin-Sanchez AM: Invasive group B streptococcal disease in nonpregnant adults. Eur J Clin Microbiol Infect Dis 2001; 20: 837-839.